Thomas Biancardi
Profile
Thomas Biancardi worked as a Director of Operations Planning & Analysis at Pfizer Inc. and as a Senior Director of Finance & Operations at Oldtech, Inc. He also worked as the Head of Investor Relations and VP of Finance & Operations at IVERIC bio, Inc. from 2013 to 2015.
Biancardi received his undergraduate degree from Rutgers State University of New Jersey and his MBA from New York University.
Former positions of Thomas Biancardi
| Companies | Position | End |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
| IVERIC BIO, INC. | Chief Operating Officer | 31/01/2012 |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Director of Finance/CFO | - |
Training of Thomas Biancardi
| New York University | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
- Stock Market
- Insiders
- Thomas Biancardi
